AMRX vs UNH

AMRX presents a stark contrast between operational success and financial instability, evidenced by a stable Piotroski F-Score of 4/9 but a critical Debt/Equity ratio of 450.96. While the company shows explosive YoY EPS growth of 75% and a highly attractive Forward P/E of 10.87, its negative book value and a significant gap between the current price ($12.87) and intrinsic value ($1.54) signal high risk. Analyst sentiment remains strongly bullish with a $17 target, yet insider selling and a bearish technical trend suggest caution. The investment thesis relies entirely on continued earnings acceleration to outpace its precarious balance sheet.

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.